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Alzheimer's Disease and Non-Insulin-Dependent Diabetes
Mellitus: Common Features Do Not Make Common
Bedfellows
A lzheimer's Disease (AD) and non-insulin-dependent dia-betes mellitus (NIDDM) are two of the most common
and devastating health problems afflicting older adults. AD
and NIDDM share a number of common features. Both
conditions can have an enormous impact on a patient's
quality of life, and both are associated with substantial health
care costs. AD and NIDDM both have names that contain
little useful information. AD is named after an obscure pa-
thologist primarily to avoid use of a term that would convey
directly its devastating impact on cognitive functioning.
NIDDM is a non name that obscures the reality that many
patients with NIDDM are in fact treated with insulin. Fur-
thermore, a substantial proportion of patients with NIDDM
rarely or never have significant amounts of sugar in their
urine, certainly not enough to give their urine the sweet taste
which is the basis for the name diabetes mellitus.
Both AD and NIDDM are subjects of intensive investi-
gation by the scientific community, and substantial resources
of relevant NIH institutes are committed to support research
about them. Perhaps my only tangible qualification to write
about both disorders is that I serve on the advisory board of
two NIH-supported Center grants at the University of Mich-
igan: the Michigan Diabetes Research and Training Center
and the Michigan Alzheimer's Disease Research Center. At
this time, a major research emphasis both in NIDDM and in
AD is the search for genetic markers for these conditions,
since both have a genetic predisposition. Specific genetic
defects have now been identified in a small number of families
with NIDDM! and with AD.2 The information obtained thus
far suggests that there may be considerable heterogeneity in
the genetic factors which contribute to both of these condi-
tions.
The importance of genetic markers to advance under-
standing of these disorders relates, in part, to the difficulty in
establishing the clinical phenotype for both NIDDM and AD.
Thus, studies relating clinical phenotype to genotypic mark-
ers are particularly important. In this issue of the Journal of
the American Geriatrics Society, Nielson et al. have used
apolipoprotein-E genotyping to correlate with the clinical
phenotype in 265 dementia patients participating in a Uni-
versity-based Alzheimer's Disease Research Center Clinic."
Included in this population were 15 patients who also had
diabetes mellitus by history. In confirmation of findings from
other studies (reference 4 and others referenced by Nielson et
al.), they found a high prevalence rate of apo-E4 and a low
prevalence rate of apo-E2 in patients meeting criteria for
possible or probable AD. Patients with other clinical types of
dementia and those dementia patients with diabetes mellitus
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had apo-E genotype distribution similar to the general popu-
lation.
See also p 897
The apoprotein-E genotype may playa pathophysiological
role in the formation of the amyloid plaques that are charac-
teristic of AD. 2,s Some evidence suggests that apo-E may
interact with the beta-amyloid protein, a secreted product of
the amyloid precursor protein or APp,6 to influence its ter-
tiary structure." The presence of apo-E4 may affect the ter-
tiary structure of beta-amyloid protein to make it more likely
to form non-soluble amyloid, thereby contributing to the
formation of amyloid plaques, whereas the apo-E2 form may
stabilize beta-amyloid protein and prevent formation of the
non-soluble form of amyloid,
Here too there is a convergence between AD and
NIDDM. Deposition of amyloid deposits in pancreatic islet
beta cells appears to be a consistent pathologic marker in
NIDDM, An islet peptide known as amylin (also known as
islet amyloid polypeptide or lAPP, not to be confused with
APP!) has been identified as the key component of such
amyloid deposits." Amylin is colocalized and cosecreted with
insulin, but its physiologic role is unknown." Although amy-
lin and beta amyloid protein are both cell secretory products,
and both have the propensity under some circumstances to
form insoluble amyloid fibrils that are toxic to host cells,s,1O
it should be emphasized that the polypeptides themselves are
completely different. While the role of either of these mole-
cules in the primary pathogenesis of AD or NIDDM is still
unclear, it is tempting to speculate that an alteration in
protein folding!' leading to aggregation and amyloid depos-
its may be a key mechanism in both diseases.
Because of these common features of AD and NIDDM,
one might postulate that it would be common to find both
conditions in given susceptible individuals, However the op-
posite may be true, Nielson et al. found that only one of the
15 people with a diagnosis of diabetes in their dementia
population met criteria for AD, representing only 0.8% of the
AD group, perhaps 10% or less of the expected prevalence
rate of NlDDM in an older population.V This finding agrees
with other reports suggesting a low prevalence rate of
NIDDM among patients with AD. What is the explanation
for this finding?
As Nielson et al. point out in their paper, there are a
number of factors in their study and others in this area that
limit the ability to draw firm conclusions about the relation-
ship, or lack thereof, between a diagnosis of AD and
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NIDDM. Since none of the studies to date are population
based, patient selection can be a confounding factor. It is
conceivable that patients with NIDDM who also have de-
mentia are less likely to end up in a research oriented clinic for
cognitive disorders than patients with dementia who do not
have diabetes mellitus. A more serious concern is the problem
of phenotype characterization. Clinical criteria for AD virtu-
ally exclude anyone with identifiable cerebrovascular disease.
Given the high prevalence of evidence of cerebrovascular
disease among older patients with NIDDM, many NIDDM
patients are automatically excluded from the AD category.
This is where the genotyping carried out by Nielson et al. may
be helpful. If a high percentage of the NIDDM patients in
their sample indeed had unrecognized AD, one might have
expected a higher prevalence of the apo-E4 genotype. There is
also a major phenotype problem regarding the diagnosis of
NIDDM. Population-based studies in the United States sug-
gest that up to 50% of patients who meet current diagnostic
criteria for NIDDM have not been diagnosed.':' Thus, the
true prevalence of NIDDM among the AD patients in the
paper by Nielson et al. cannot be established in the absence of
specific testing of glucose tolerance status. The diagnosis of
diabetes in this study was based entirely on clinical history.
Only a minority of the patients had even a fasting serum
glucose level tested.
More intriguing would be the possibility that some as-
pect of AD prevents NIDDM and/or some aspect of NIDDM
protects against AD. A simple hypothesis is that the weight
loss that often accompanies AD 14 leads to a reduction in
obesity-related insulin resistance, thereby tending to prevent
the development of hyperglycemia. Could there be a positive
benefit of chronic hyperglycemia to reduce the rate of devel-
opment of degenerative pathologic lesions in the brain by
simply enhancing access of brain tissue to an important fuel?
There is evidence that reduced neuronal oxidative metabo-
lism, a possible consequence of low fuel availability, can
result in a change in APP processing that increases the likeli-
hood that beta-amyloid peptide will be produced.P Could
adaptive mechanisms in response to one disorder of protein
folding reduce the likelihood of development of a second such
disorder? For example, if there are generalized antiprotein
aggregation biochemical responses to the formation of aggre-
gated protein resulting from a genetic defect of overproduc-
tion of an amyloid precursor protein, such mechanisms might
reduce the likelihood of accumulation of protein aggregates
in other tissues. Clearly, additional work is needed to first
determine whether the presence of AD or NIDDM actually
reduces risk for the other condition, and, if so, what mecha-
nisms might contribute to such protection.
Jeffrey B. Halter, MD
University of Michigan Medical School and
Geriatric Research Education and Clinical Center
Veterans Affairs Medical Center, Ann Arbor, MI
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